APTEVO
They regard themselves as self-contained, owner-managed businesses with quick decision-making cycles. Their clients work in a variety of industries and are either SMEs or huge corporations. They work together to discover and implement solutions for everything from comprehensive IT infrastructure support to the very particular demands of larger IT departments. Companies in the business sector, state entities, and private and public schools are among their clients. They have mainly moved in the fo... llowing subject areas: continuous integration, continuous deployment, and continuous delivery infrastructure management according to DevOps principles, servers & virtualization, network, storage, client management & virtualization, internet connection & security, monitoring, automation & scripting, OS migrations, penetration testing, resiliency, Linux and open-source, in-house, cloud solutions, messaging.
APTEVO
Industry:
DevOps Internet Of Things IT Infrastructure Management Information Systems Small And Medium Businesses Software
Founded:
2011-01-01
Address:
Pratteln, Basel-Landschaft, Switzerland
Country:
Switzerland
Website Url:
http://www.aptevo.ch
Total Employee:
1+
Status:
Active
Contact:
+41 61 511 0855
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Domain Not Resolving SPF Apple Mobile Web Clips Icon Google Font API LetsEncrypt SSL By Default Font Awesome Mobile Non Scaleable Content
Similar Organizations
9apps
9apps is a provider of cloud based infrastructures and devops services.
ASPEX
ASPEX provides information technology services.
Automation Consultants
Automation Consultants is a consulting firm that offers devops, training, and cloud solutions.
Bitergo
Bitergo provides logistics software solutions and consulting services.
DAERO
DAERO provides software for businesses.
ICU IT
ICU IT provides information technology and services.
ISD Moldova
ISD is an extensive outsourcing provider that is committed to creating a consistent customer experience.
Stackmasters
Stackmasters provides cloud management and application hosting solutions for private, public and hybrid clouds.
Vtenext
Vtenext is a software development company that offers cloud-based CRM, open source CRM, add-ons, and plug-ins.
Official Site Inspections
http://www.aptevo.ch
- Host name: 212.243.197.119
- IP address: 212.243.197.119
- Location: Onex Switzerland
- Latitude: 46.1877
- Longitude: 6.0981
- Timezone: Europe/Zurich
- Postal: 1213
More informations about "Aptevo"
Aptevo Therapeutics | About Us
Aptevo Therapeutics is a biotech company focused on bringing novel immuno-oncology therapeutics to market. We leverage the innovative and proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies to create …See details»
Aptevo Therapeutics - Crunchbase Company Profile
Aptevo Therapeutics is a biotech company primarily focused on bringing novel oncology and hematology therapeutics to market. They leverage the innovative ADAPTIR™ platform technology, a unique approach to cancer …See details»
Aptevo - Crunchbase Company Profile & Funding
Aptevo is located in Pratteln, Basel-Landschaft, Switzerland. Who are Aptevo 's competitors? Alternatives and possible competitors to Aptevo may include …See details»
Aptevo Therapeutics executes reverse stock split
4 days ago Aptevo Therapeutics, headquartered in Seattle, Washington, operates under the organization name 03 Life Sciences and is incorporated in Delaware. The company's fiscal …See details»
Willkommen bei Aptevo!
Willkommen bei Aptevo! Lösungen, Produkte und Dienstleistungen für Ihre Informatik-Infrastruktur. Hersteller, Partner und Produkte. Mit diesen Herstellern, Partnerfirmen und Produkten arbeiten wir regelmässig und gerne. Wer sind …See details»
Aptevo Therapeutics executes reverse stock split - za.investing.com
4 days ago Aptevo Therapeutics, headquartered in Seattle, Washington, operates under the organization name 03 Life Sciences and is incorporated in Delaware. The company's fiscal …See details»
Aptevo Therapeutics Inc. Announces Closing of Previously …
Aug 4, 2023 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical stage biotechnology company focused on developing novel immuno-oncology therapeutics, …See details»
Aptevo Highlights the Potential of the Company's Robust Portfolio …
Nov 22, 2024 Aptevo's focused yet diversified pipeline aligns with these industry trends, offering a compelling investment opportunity that may address critical therapeutic gaps," said Marvin …See details»
Aptevo Therapeutics Inc | LinkedIn - LinkedIn Schweiz
Aptevo Therapeutics Inc | 3.104 Follower:innen auf LinkedIn. Our innovative ADAPTIR™ platform technology brings a unique approach to cancer immunotherapy and improves outcomes. | …See details»
Aptevo Therapeutics | Technology
ADAPTIR Bispecifics are based on a robust technology platform with potential advantages over other platforms including; Increased stability and half-life, antibody-like manufacturing, ease of transfer and manufacturing at CMOs.. …See details»
Proving the Concept: Aptevo Technology, Pipeline, to Exemplify …
Nov 26, 2024 There are several important factors that could cause Aptevo's actual results to differ materially from those indicated by such forward-looking statements, including a …See details»
Proving the Concept: Aptevo Technology, Pipeline, to Exemplify …
Nov 26, 2024 The presentation will illustrate how Aptevo leverages its proprietary platforms to rapidly advance the development of innovative cancer therapies and use clinical candidates …See details»
Aptevo Therapeutics effectue un regroupement d'actions
4 days ago Aptevo a levé 2,3 millions $ dans une offre directe et a fixé les conditions d'une offre publique de 4,6 millions $. Roth/MKM a révisé l'objectif de cours d'Aptevo à 8,00$, maintenant …See details»
Aptevo reports progress in cancer antibody trials - Investing.com
Nov 22, 2024 Aptevo's preclinical assets, APVO711, APVO603, and APVO442, are also advancing, focusing on safety and targeted efficacy. The company expects to add another …See details»
First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves …
Nov 20, 2024 Mipletamig has been evaluated in 90 patients over two trials to date. RAINIER, Aptevo's Phase 1b/2 frontline AML program, was initiated in 3Q24. About Aptevo …See details»
Aptevo Highlights the Potential of the Company's Robust
Nov 22, 2024 Aptevo Therapeutics, a leader in the development of novel bispecific antibodies for cancer treatment, provided additional details about its robust oncology pipeline which is poised …See details»
Aptevo Therapeutics | Pipeline
Aptevo Therapeutics is committed to building a robust pipeline of preclinical ADAPTIR™ and ADAPTIR-FLEX™ bispecifics with a focus on novel mechanisms of action. By leveraging our …See details»
Aptevo Therapeuticsが株式併合を実施 執筆： Investing.com
4 days ago シアトル - 医薬品製剤を専門とするバイオテクノロジー企業Aptevo Therapeutics Inc. (NASDAQ:APVO)は、火曜日付で普通株式の株式併合を実施したと発表しました。 この …See details»
Aptevo Therapeutics | Mipletamig
Aptevo’s lead proprietary drug candidate, mipletamig is a bispecific CD3xCD123 ADAPTIR molecule that is designed to redirect the patients’ immune system to destroy leukemia cells …See details»